Highlight key findings in the KRYSTAL-7 trial.
Stay up to date on practice-changing data in community practice.
Higher AFM24 Exposure Boosts Response in Advanced NSCLC: AACR Data
A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.
Read More
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Listen
Ivonescimab Plus Chemo Shows Stronger NSCLC Response Than Tislelizumab Combo
Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers
Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.
Savolitinib/Osimertinib Yields Durable Responses in EGFR-Mutated, MET+ NSCLC
The phase 2 SAVANNAH trial of savolitinib plus osimertinib has demonstrated the combination’s efficacy and safety in EGFR-mutated NSCLC.
